![[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]](https://cddf.org/wp-content/uploads/2026/06/Copy-of-PUBLICATION-Annual-Repport-2024-Is-available-6-1080x675.jpg)
CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova
🔔📢 CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova The Cancer Drug Development Forum (CDDF) is pleased to announce the appointment of Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova to its Board of Directors. We look forward to...
Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Use of AI in Clinical Trials” (12 May 2026)
The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Use of AI in clinical trials” held on 12 May 2026. This webinar included a lecture by Dr. James Gulley (NIH) followed by a 30-minute Q&A...![[ACT EU Workplan for 2026-2027 – Version 4, May 2026]](https://cddf.org/wp-content/uploads/2026/05/Capture-1080x675.jpg)
[ACT EU Workplan for 2026-2027 – Version 4, May 2026]
The ACT EU workplan for 2026 – 2027 has been adopted by the ACT EU Steering Group and is now published. The workplan reflects the revised ACT EU objectives and takes into account recent legislative and policy developments including the proposed Biotech Act, the...